ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)

GRACEcast Cancer 101 Audio
16/08/2013 6 min
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)

Listen "ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.

More episodes of the podcast GRACEcast Cancer 101 Audio

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy? 31/07/2014
Management of Rare Kidney Tumors 29/07/2014
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation? 27/07/2014
NanoString Treatment for Kidney Cancer 24/07/2014
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer? 22/07/2014
How is the Heng Criteria Applied to Kidney Cancer Patients? 20/07/2014
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? 17/07/2014
What is PD1 and PDL1 in Kidney Cancer? 15/07/2014
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope 13/07/2014
No Clear Answer for Non-Clear Cell Kidney Cancer 10/07/2014
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA